Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety of Quadrivalent Subunit Influenza Vaccine in ≥3-year-old population
CTR20244333Phase 4Completed
- Sponsor
- Ab&B Bio-tech Co., Ltd.
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of quadrivalent influenza virus subunit vaccine (Ab&B Bio-tech) in influenza, sponsored by Ab&B Bio-tech Co., Ltd.. Started Dec 2024; status: completed.
02
Drugs
quadrivalent influenza virus subunit vaccine (Ab&B Bio-tech)
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20244333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244333.